| |
|
|
| |
|
|
Dr. Hung T. Khong (left) and Dr. Philip M. Wade (right)
Appointments: 251-665-8000 |
| |
| Cancer Physicians Now Accepting New Patients |
|
| |
|
| The University of South Alabama Cancer Research Institute announces the opening of the clinical practices of Medical Oncologists Philip M. Wade, Jr., M.D. and Hung T. Khong, M.D. |
|
| |
| Drs. Philip M. Wade Jr. and Hung T. Khong, both medical oncologists, provide adult medical oncology care. Khong, a physician-researcher, will also be involved in pre-clinical and clinical research studies. Wade serves as chief of the medical oncology service at the USA Cancer Research Institute and has a faculty appointment as associate professor of internal medicine in the USA College of Medicine. |
|
| |
| Khong splits his time between research and clinical activities, serving as head of the Clinical Immunotherapeutics Research Laboratory and a staff medical oncologist with the USA Cancer Research Institute. He also has a faculty appointment as assistant professor of internal medicine at the USA College of Medicine. |
| |
|
|
|
| |
|
|
Innovative Researcher and Physician
Dr. Hung T. Khong, M.D. |
| |
| Before accepting his post at the USA Cancer Research Institute, Khong was a senior clinical fellow in the surgery branch of the national Cancer Institute located in Bethesda, Md. From 1997-2000, he was a clinical fellow in medical oncology in the medicine branch also at NCI. |
| |
| Khong received his doctorate of medicine degree from Temple University School of Medicine in Philadelphia, Pa. He completed his residency in internal medicine at the Baylor College of Medicine in Houston. |
| |
At the National Cancer Institute, Khong trained with the brightest minds in cancer research. Khong was awarded the NCI Center for Cancer Research Senior Fellowship Training Award in 2000, an extremely competitive three-year training grant presented to the most outstanding clinical fellows in the Center for Cancer Research at NCI.
|
| |
| Khong's research centers on immunotherapy, a new and expanding field that uses the body's natural defense mechanisms as a basis for creating new therapies for diseases and a variety of chronic medical conditions including cancer. Khong is working to develop methods to harness and enhance the body's natural tendency to defend itself against cancer. |
| |
| Khong is board certified in internal medicine and medical oncology. He has a U.S. patent pending for his identification of TRP-2 isoform that contains HLA-A2 restricted T-cell epitopes - a technology that may lead to the development of a new anti-cancer vaccine. |
|
Experienced Physician
Dr. Philip M. Wade Jr., M.D. |
| |
Prior to his appointment with the USA Cancer Research Institute, Wade was a private physician practicing in southeast Alabama with South Alabama Oncology, P.C., which has offices in Andalusia and Opp, Ala. He has also practiced in Baton Rouge, La., and Pensacola, Fla.
|
| |
| Wade, a native of Dover, N. J., received his doctorate of medicine degree from Tufts University School of Medicine in Boston, Mass. He completed his internship and residency training in internal medicine at the University of Alabama Medical Center in Birmingham, Ala. |
| |
| From 1981 to 1982, Wade was a clinical fellow in hematology/oncology at the University of Virginia Hospital in Charlottesville, Va. From 1982 to 1983, he was a research fellow at UVA Hospital, and served as a clinical fellow in hematology/oncology from 1983 to 1984. He is a diplomate in the American Board of Internal Medicine, and in the subspecialties of medical oncology and hematology. |
| |
| He is a member of numerous professional organizations including the American Medical Association, the American Society of Clinical Oncology, and the American Society of Hematology. He has participated in several national clinical research trials, serving as an investigator for the Southeast Cancer Study Group and the Southwest Oncology Group. |
| |
| From 1998 to 2001, he was a principal investigator in the National Surgical Adjuvant Breast and Bowel Project P-2 Trial, which studied the use of Tamoxifen and Raloxifen for prevention of breast cancer. |
| |
|
|